Audeo Oncology (Audeo Oncology) Price-to-Tangible-Book : (As of May. 15, 2024)

View and export this data going back to . Start your Free Trial

What is Audeo Oncology Price-to-Tangible-Book?

As of today (2024-05-15), Audeo Oncology's share price is $0.00. Audeo Oncology's Tangible Book per Share of Sep. 2012 for the quarter that ended in Sep. 2012 was $0.00. Hence, Audeo Oncology's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Audeo Oncology's Price-to-Tangible-Book or its related term are showing as below:

AURX's Price-to-Tangible-Book is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 2.41
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Audeo Oncology's share price is $0.00. Audeo Oncology's Book Value per Sharefor the quarter that ended in Sep. 2012 was $0.00. Hence, Audeo Oncology's P/B Ratio of today is .

Audeo Oncology Price-to-Tangible-Book Historical Data

The historical data trend for Audeo Oncology's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audeo Oncology Price-to-Tangible-Book Chart

Audeo Oncology Annual Data

Trend

Jun10

Jun11

Jun12

Price-to-Tangible-Book

Audeo Oncology Quarterly Data
	Jun11	Mar12	Jun12	Sep12
Price-to-Tangible-Book	-	-	-	-

Competitive Comparison of Audeo Oncology's Price-to-Tangible-Book

For the Drug Manufacturers - General subindustry, Audeo Oncology's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Audeo Oncology's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Audeo Oncology's Price-to-Tangible-Book falls into.

Audeo Oncology Price-to-Tangible-Book Calculation

Audeo Oncology's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Sep. 2012 )
	=	0.00	/
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Audeo Oncology Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Audeo Oncology (Audeo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » Price-to-Tangible-Book

Traded in Other Exchanges

N/A

Address

Website

http://www.audeooncology.com

Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.